GSK Signs Exclusive Agreement with Chongqing Zhifei Biological Products


In an exciting development, GSK has announced that Chongqing Zhifei Biological Products will be acquiring their highly sought-after shingles vaccine, Shingrix. This exclusive agreement, valued at a staggering 2.5 billion pounds ($3.06 billion), gives Zhifei sole rights to import and distribute Shingrix in China. The initial contract period will span three years, commencing on January 1, with the potential for an extension.

GSK is confident that this partnership will not only meet the increasing demand for the vaccine but also drive the company’s commitment to double global sales of Shingrix. With a target of surpassing GBP4 billion by 2026, GSK aims to create a significant impact on the global market.

Furthermore, this collaboration will greatly enhance accessibility to the vaccine for healthcare professionals and over 30,000 vaccination points. GSK predicts a phased increase in production over the contract period to meet the escalating demand.

Zhifei, as the leading Chinese vaccine company in terms of revenue, is well-positioned to maximize the potential of this exclusive partnership. This strategic alliance may also pave the way for future collaborations, specifically concerning GSK’s respiratory syncytial virus vaccine, Arexvy. Although currently not approved in China, this agreement sets the stage for potential co-development and commercialization opportunities.

Overall, GSK’s venture with Zhifei represents a significant milestone in expanding the availability and impact of their vaccines in China. The future looks promising for both parties involved as they work together to tackle pressing healthcare needs.

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Another Tough Quarter for Banks

Next Post

Oil Stocks Rally as Israel Attack Sends Crude Oil Prices Soaring

Related Posts